BLOODOMICS - Identification of risk genes for atherothrombosis in coronary artery disease by transcriptome and proteome analysis and high throughput exon resequencing (Life sciences, genomics and biotechnology for health) (2004-06-01 - 2008-05-31) (»add to infobox)

Coronary artery disease (CAD) and atherothrombosis (AT) kills more individuals in Europe than any other disease. 600,000 people are diagnosed with myocardial infarction (Ml) yearly, with 50% being fatal and many survivors experiencing a reduction in quality of life. Long-term aspirin provides a cheap approach to the prevention of Ml. However, its use is associated with unacceptable side effects, thus emphasising the need for the identification of markers to detect individuals at risk of CAD and AT. Such markers are not currently available. However, completion of the human genome sequence and high-throughput sequencing and typing of single nucleotide polymorphisms, together with new technologies such as microarray analysis, proteomics and RNA interference, provide a unique opportunity for their identification. Development of better drugs for the prevention and treatment will also be facilitated by a greater understanding of the mechanisms of platelet interaction with the damaged vessel wall and with other blood cells. We bring together leading European scientific and medical expertise to reap the benefits of the completion of the human genome, by identifying genetic risk factors for CAD & AT through research that spans the clinical-basic science interface. Our studies will result in health gains and wealth creation. The project will generate population genetics data providing insight into the causes of CAD & AT through the identification of contributory genes and gene variants, proteins and intracellular signalling pathways. Our globally competitive programmes of cell biology and protein research will determine the physiological roles of identified proteins. The likelihood of achieving our ambitious goals is greatly increased by bringing together five leading clinical CAD centres, academic groups specialised in cell biology/signalling/haematopoieses and proteomics as well as Europe's premier genome centre, The Wellcome Trust Sanger Institute. Keywords: Proteomics, microarray, platelets, myocardial infarct

COORDINATOR (1/1)

PARTICIPANTS (12/12)

RELATED THEMATIC AREAS (1/1)